[
  {
    "id": 0,
    "type": "Contribution",
    "agent_id": 0,
    "description": "Initial access of FDA approvals",
    "date": "2024-10-30"
  },
  {
    "id": 1,
    "type": "Contribution",
    "agent_id": 0,
    "description": "Additional FDA approvals for initial version",
    "date": "2025-01-10"
  },
  {
    "id": 2,
    "type": "Contribution",
    "agent_id": 0,
    "description": "April 2025 database release, FDA provided regular approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for patients with gastric or gastroesophageal junction (GEJ) adenocracinoma.",
    "date": "2025-04-01"
  },
  {
    "id": 3,
    "type": "Contribution",
    "agent_id": 0,
    "description": "Added propositions and statements for FDA approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Added additional propositions for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997)."
  }
]